J.J. Braun

1.6k citations

11 papers · 1.1k indexed · 1 hit paper · h-index 8

Cardiology and Cardiovascular Medicine top 2%
Surgery
Oncology
Endocrinology, Diabetes and Metabolism top 10%
Nutrition and Dietetics top 10%

Co-authors: Robert Fagard Peter Gheeraert Patricia Van der Niepen Peter W. de Leeuw R. Six Luc Missault Eoin OʼBrien Denis Clément
Topics: Cancer Treatment and Pharmacology (5 papers)Vitamin D Research Studies (3 papers)Colorectal Cancer Treatments and Studies (2 papers)
Cited by: Cardiology and Cardiovascular Medicine Geriatrics and Gerontology Nutrition and Dietetics
Journals: New England Journal of Medicine Journal of Clinical Oncology Annals of Oncology
Partner nations: Netherlands United States Belgium

In The Last Decade

J.J. Braun

11 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension

2003 803 citations Denis Clément, Marc De Buyzere et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by J.J. Braun

Since Specialization

Citations

This map shows the geographic impact of J.J. Braun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.J. Braun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.J. Braun more than expected).

Fields of papers citing papers by J.J. Braun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.J. Braun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.J. Braun. The network helps show where J.J. Braun may publish in the future.

Co-authorship network of co-authors of J.J. Braun

This figure shows the co-authorship network connecting the top 25 collaborators of J.J. Braun. A scholar is included among the top collaborators of J.J. Braun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.J. Braun. J.J. Braun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG 2014 ·Annals of Oncology ·Carolien H. Smorenburg,(unknown),A. Elise van Leeuwen‐Stok,Marije E. Hamaker,A.N.M. Wymenga,H. de Graaf,Felix E. de Jongh,J.J. Braun,Maartje Los,E. Maartense,Harm van Tinteren,J.W.R. Nortier,Caroline Seynaeve	43
2	Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial 2014 ·European Journal of Cancer ·Siu W. Lam,(unknown),A.H. Honkoop,Agnes Jager,Albert J. ten Tije,Monique M.E.M. Bos,SC Linn,Jackie Bosch,Judith R. Kroep,J.J. Braun,Harm van Tinteren,Epie Boven	25
3	Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group 2013 ·The Breast ·Marije E. Hamaker,Caroline Seynaeve,A.N.M. Wymenga,Harm van Tinteren,J.W.R. Nortier,E. Maartense,H. de Graaf,Felix E. de Jongh,J.J. Braun,Maartje Los,Jolanda Schrama,A. Elise van Leeuwen‐Stok,(unknown),Carolien H. Smorenburg	108
4	Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X). 2013 ·Journal of Clinical Oncology ·Siu W. Lam,(unknown),Aafke H. Honkoop,Nienke M. Nota,Agnes Jager,Ankie M.T. van der Velden,Monique M.E.M. Bos,Sabine C. Linn,(unknown),Judith R. Kroep,J.J. Braun,Richard R. de Haas,Carolien H. Smorenburg,Hiltje de Graaf,(unknown),Maartje Los,(unknown),Harm van Tinteren,Epie Boven,(unknown)	3
5	Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). 2013 ·Journal of Clinical Oncology ·Miriam Koopman,Lieke H. J. Simkens,Albert J. ten Tije,Geert‐Jan Creemers,O. J. L. Loosveld,Felix E. de Jongh,Frans Erdkamp,Z. Erjavec,(unknown),(unknown),Peter Nieboer,J.J. Braun,Slinger Jansen,(unknown),Annemieke Cats,(unknown),Linda Mol,Otilia Dalesio,Harm van Tinteren,Cornelis J.A. Punt	39
6	Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertensionbreakdown → 2003 ·New England Journal of Medicine ·Denis Clément,Marc De Buyzere,(unknown),Peter W. de Leeuw,Daniel Duprez,Robert Fagard,Peter Gheeraert,Luc Missault,J.J. Braun,R. Six,Patricia Van der Niepen,Eoin OʼBrien	803
7	671 Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC) 2003 ·European Journal of Cancer Supplements ·M. Bontenbal,J.J. Braun,G.J. Creemers,A C de Boer,Jan Janßen,Mark Leys,(unknown),P.I.M. Schmitz,(unknown),C. Seynaeve	16
8	Glucocorticoids, vitamin D and bone : a pathophysiologic and therapeutic study of glucocorticoid-induced bone disease 1984 ·RePub (Erasmus University Rotterdam) ·J.J. Braun	2
9	INFLUENCE OF 1α‐(OH)D₃ ADMINISTRATION ON BONE AND BONE MINERAL METABOLISM IN PATIENTS ON CHRONIC GLUCOCORTICOID TREATMENT; A DOUBLE BLIND CONTROLLED STUDY 1983 ·Clinical Endocrinology ·J.J. Braun,D.H. Birkenhäger-Frenkel,(unknown),J.R. Juttmann,T.J. Visser,J.C. Birkenhäger	58
10	SHORT‐TERM EFFECT OF PREDNISONE ON SERUM 1,25‐DIHYDROXYVITAMIN D IN NORMAL INDIVIDUALS AND IN HYPER‐AND HYPOPARATHYROIDISM 1982 ·Clinical Endocrinology ·J.J. Braun,J.R. Juttmann,T.J. Visser,J.C. Birkenhäger	29
11	LACK OF RESPONSE OF 1,25‐DIHYDROXYCHOLECALCIFEROL TO EXOGENOUS PARATHYROID HORMONE IN A PATIENT WITH TREATED PSEUDOHYPOPARATHYROIDISM 1981 ·Clinical Endocrinology ·J.J. Braun,J.C. Birkenhäger,T.J. Visser,J.R. Juttmann	4

About J.J. Braun

J.J. Braun is a scholar working on Nephrology, Oncology and Geriatrics and Gerontology, having authored 11 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (5 papers), Vitamin D Research Studies (3 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (734 citations), Geriatrics and Gerontology (95 citations) and Nutrition and Dietetics (112 citations). J.J. Braun has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Robert Fagard, Peter Gheeraert, Patricia Van der Niepen, Peter W. de Leeuw, R. Six, Luc Missault, Eoin OʼBrien, Denis Clément, Daniel Duprez and Marc De Buyzere. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact